Oct 05, 2020 / 06:00PM GMT
Yevgeniya Livshits - Chardan Capital Markets, LLC, Research Division - Senior Research Analyst
Hello, and apologies for the slight delay. It's now my pleasure to introduce our fireside chat guest, Dr. Stephen Hoge, President of Moderna.
So Stephen, thank you for joining us today. (Operator Instructions)
So to start off, Stephen, would you provide a brief couple of minutes of introductory comments on Moderna to frame for us where Moderna is today relative to where it was last year when you guys presented at our conference?
Stephen Hoge - Moderna, Inc. - President
Of course. Well, first of all, thank you for the opportunity to present and join you today. It feels like -- it may have only been a year on a calendar, but it feels like it's been a couple of decades in all of our experiences since I last had a chance to speak to the conference. I -- where to start? It's hard not to say the word COVID when talking about what's happened to Moderna over the last few years, but I'm going to try and make that my last sort of comment in the news of the
Moderna Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers